Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

Zynyz (retifanlimab) is a late entrant to the PD-1/PD-L1 category ... in its cancer pipeline. CDK2 drug shows promise Those include potential first-in-class CDK2 inhibitor INCB123667, which ...

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

Iovance Biotherapeutics' strong Q3 earnings and promising drug pipeline suggest growth potential for risk-tolerant investors.

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...

Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic colorectal cancer: Princeton, New Jersey Monday, November 18, 2 ...

BioNTech to acquire clinical-stage biotech company, Biotheus to boost oncology strategy: Mainz, Germany Friday, November 15, 2024, 14:00 Hrs [IST] BioNTech SE and Biotheus (Biothe ...